Here's the latest I've heard regarding Enzalutamide. Two points of note. First, this study indicates benefit if taken before chemo. Second, the MedPage Today article indicates additional benefit if taken with radiation treatment.
Enzalutamide May Prolong Lives, Delay Tumor Progression In Men With Advanced Prostate Cancer.
The New York Times (1/29, Pollack, Subscription Publication) reports that research indicated that “Xtandi [enzalutamide] prolonged lives and delayed tumor progression when used before chemotherapy in a study of men with advanced” prostate cancer. Investigators found that “the estimated median survival for the men who received Xtandi was 32.4 months after taking the drug compared with 30.2 months for those who received a placebo, a difference that was statistically significant.” The study also indicated that the medication “reduced the risk of the cancer worsening by 81 percent.” http://www.nytimes.com/2014/01/29/health/drug-shows-promise-in-advanced-prostate-cancer-when-used-before-chemotherapy.html?_r=0
Reuters (1/29, Berkrot) reports that the findings were released yesterday, ahead of presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium. The findings may lead to an expanded approval for the medication. http://www.reuters.com/article/2014/01/28/us-medivation-prostate-idUSBREA0R1VE20140128
HealthDay (1/29, Gordon) reports that the medication is already FDA-approved “for use in men with advanced prostate cancer who have received chemotherapy.” http://consumer.healthday.com/cancer-information-5/mis-cancer-news-102/drug-extends-survival-for-men-with-advanced-resistant-prostate-cancer-684296.html
The Oncology Report (1/29, London) reports that the medication “was well tolerated and not associated with an increase in the rate of treatment discontinuation because of adverse events.” http://www.oncologypractice.com/oncologyreport/news/top-news/single-view/enzalutamide-improves-survival-in-chemo-naive-metastatic-prostate-cancer/f9e2ab74cb9209e280d396b942e8257d.html
MedPage Today (1/29, Bankhead) reports on the enzalutamide study, and adds that “another study reported at the press briefing confirmed and extended results from a large randomized trial that compared life-long hormonal therapy with or without radiation therapy.” The “initial reports showed that the addition of radiation therapy was associated with a 50% improvement in 10-year survival in men with nonmetastatic advanced prostate cancer.” MedPage Today adds, “In an update of the results, Sophie D. Fossa, MD, PhD, of the Norwegian Radium Hospital in Oslo, reported that patients who received external-beam radiation therapy in addition to anti-androgen therapy had a prostate cancer-specific mortality of 12% at 15 years versus 31% for patients who received hormonal therapy alone.”
52 at Dx (3/12/10), father died of PCa
PSA: 10/16/09 - 2.8; 1/11/10 - 3.8; since RALP - <0.1
RALP 5/19/10, Dr. Lee, U. Penn Presby
Gleason 6, gland involvement < 2%; tumor in peripheral zone both sides; no capsular, extracapsular extension, lymph node, or seminal vesical involvement; no positive margins
Incontinence: no pads except at karate
ED: no issue